Behçet's Syndrome: an Update

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2003 May 15

PMID 12744810

Citations 11

Authors

Hasan Yazici

Affiliations

Soon will be listed here.

Abstract

The pathogenic mechanisms in Behçet's syndrome are largely unknown. An autoantigen role for human leukocyte antigen B51 has been proposed. The reasons behind the thrombophilia are also not clear. Endothelial pathology could be the main culprit. The recently proposed association between familial Mediterranean fever and Behçet's syndrome might not be well founded. The long-term prognosis is more guarded among the young and among males. However, the disease burns out in many cases. Clinicians are getting better at management, and have better understanding of the old drugs, such as colchicine, and have new and potent drugs like tumor necrosis factor-alpha inhibitors.

Citing Articles

The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet's disease: a systematic review and meta-analysis.

Mohammed R, Woldeamanuel Y J Int Med Res. 2023; 51(5):3000605231169895.

PMID: 37203384 PMC: 10201531. DOI: 10.1177/03000605231169895.

Behcet's Disease With Cerebral Artery Infarction Caused by Cerebral Arteritis as an Early Symptom Only With Elevated Interleukin-8.

Yin H, Song Y, Zheng M, Han J, Tang J Front Neurol. 2019; 10:1102.

PMID: 31695669 PMC: 6817676. DOI: 10.3389/fneur.2019.01102.

Behçet's Syndrome and Nervous System Involvement.

Uygunoglu U, Siva A Curr Neurol Neurosci Rep. 2018; 18(7):35.

PMID: 29789966 DOI: 10.1007/s11910-018-0843-5.

Epidemiology and management of neuropsychiatric disorders in Behçet's syndrome.

Talarico R, Palagini L, dAscanio A, Elefante E, Ferrari C, Stagnaro C CNS Drugs. 2015; 29(3):189-96.

PMID: 25643894 DOI: 10.1007/s40263-015-0228-0.

Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab.

Uygunoglu U, Pasha M, Saip S, Siva A J Spinal Cord Med. 2014; 38(1):111-4.

PMID: 24673549 PMC: 4293525. DOI: 10.1179/2045772314Y.0000000209.

References

Krause I, Monselise Y, Milo G, Weinberger A . Anti-Saccharomyces cerevisiae antibodies--a novel serologic marker for Behçet's disease. Clin Exp Rheumatol. 2002; 20(4 Suppl 26):S21-4. View

Kim B, Leboit P . Histopathologic features of erythema nodosum--like lesions in Behçet disease: a comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermatopathol. 2000; 22(5):379-90. DOI: 10.1097/00000372-200010000-00001. View

Direskeneli H, Bozkurt N, Ozyazgan Y, Bavbek T, Kazokoglu H, Eksioglu-Demiralp E . Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol. 2000; 120(1):162-6. PMC: 1905613. DOI: 10.1046/j.1365-2249.2000.01176.x. View

Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V, Yazici H . Gastrointestinal involvement in Behçet's syndrome: a controlled study. Ann Rheum Dis. 1996; 55(3):208-10. PMC: 1010133. DOI: 10.1136/ard.55.3.208. View

Lesprit P, Wechsler B, Piette J, Du-Boutin L, Godeau P, Alhenc-Gelas M . Activated protein C resistance caused by factor V Arg 506-->Gln mutation has no role in thrombotic manifestations of Behçet's disease. Ann Rheum Dis. 1995; 54(10):860. PMC: 1010028. DOI: 10.1136/ard.54.10.860. View

Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S . Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002; 138(4):467-71. DOI: 10.1001/archderm.138.4.467. View

Mor F, Weinberger A, Cohen I . Identification of alpha-tropomyosin as a target self-antigen in Behçet's syndrome. Eur J Immunol. 2002; 32(2):356-65. DOI: 10.1002/1521-4141(200202)32:2<356::AID-IMMU356>3.0.CO;2-9. View

Gumucio D, Diaz A, Schaner P, Richards N, Babcock C, Schaller M . Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis. Clin Exp Rheumatol. 2002; 20(4 Suppl 26):S45-53. View

Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A . Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002; 112(1):37-43. DOI: 10.1016/s0002-9343(01)01048-8. View

10.

Birlik M, Tunca M, Hizli N, Soyturk M, Yenicerioglu Y, Ozcan M . Coexistence of familial Mediterranean fever with sacroiliitis and Behçet's disease: a rare occurrence. Clin Rheumatol. 1998; 17(5):397-9. DOI: 10.1007/BF01450901. View

11.

Sfikakis P, Theodossiadis P, Katsiari C, Kaklamanis P, Markomichelakis N . Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 2001; 358(9278):295-6. DOI: 10.1016/s0140-6736(01)05497-6. View

12.

Touitou I, Magne X, Molinari N, Navarro A, Quellec A, Picco P . MEFV mutations in Behçet's disease. Hum Mutat. 2000; 16(3):271-2. DOI: 10.1002/1098-1004(200009)16:3<271::AID-HUMU16>3.0.CO;2-A. View

13.

Lee C, Kim W, Cho Y, Kim M, Kim J, Park I . Colonoscopic findings in intestinal Behçet's disease. Inflamm Bowel Dis. 2001; 7(3):243-9. DOI: 10.1097/00054725-200108000-00010. View

14.

Tokay S, Direskeneli H, Yurdakul S, Akoglu T . Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology (Oxford). 2001; 40(2):192-5. DOI: 10.1093/rheumatology/40.2.192. View

15.

Tunc R, Uluhan A, Melikoglu M, Ozyazgan Y, Ozdogan H, Yazici H . A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome. Clin Exp Rheumatol. 2002; 19(5 Suppl 24):S45-7. View

16.

Aksu K, Turgan N, Oksel F, Keser G, Ozmen D, Kitapcioglu G . Hyperhomocysteinaemia in Behçet's disease. Rheumatology (Oxford). 2001; 40(6):687-90. DOI: 10.1093/rheumatology/40.6.687. View

17.

Verity D, Vaughan R, Madanat W, Kondeatis E, Zureikat H, Fayyad F . Factor V Leiden mutation is associated with ocular involvement in Behçet disease. Am J Ophthalmol. 1999; 128(3):352-6. DOI: 10.1016/s0002-9394(99)00184-1. View

18.

Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T . Coagulation factor V gene mutation increases the risk of venous thrombosis in behçet's disease. Br J Rheumatol. 1996; 35(11):1178-80. DOI: 10.1093/rheumatology/35.11.1178. View

19.

Gul A, Hajeer A, Worthington J, Ollier W, Silman A . Linkage mapping of a novel susceptibility locus for Behçet's disease to chromosome 6p22-23. Arthritis Rheum. 2001; 44(11):2693-6. DOI: 10.1002/1529-0131(200111)44:11<2693::aid-art449>3.0.co;2-m. View

20.

Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y . A double blind study of colchicine in Behçet's disease. Haematologica. 1980; 65(3):399-402. View